The Little Green Pharma (ASX:LGP) share price has fallen 7% this month

September hasn't been Little Green Pharma's month. Here's what the company has been up to this month.

| More on:
a medical researcher places a cannabis plant bud into a test tube. She is wearing a white lab coat and protective equipment, including a mask, over her face and is in an outdoor setting.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Little Green Pharma Ltd (ASX: LGP) share price is struggling this month despite numerous positive announcements released to the market.

On 6 September, the medical cannabis producer announced its first Danish shipment and two new appointments. Then, on 7 September, it announced it will foray into psychedelic medicines.

Unfortunately, none of Little Green Pharma's gains from the announcements have managed to stick. In fact, the company's stock has returned all its September gains and then some.

Right now, the Little Green Pharma share price is 70 cents, flat with its previous close, and 6.67% lower than its first close of this month.

Let's take a closer look at the latest news from the company.

The month so far for Little Green Pharma

The Little Green Pharma share price is having a tough slog this month despite the market reacting positively to 2 announcements.

First off, Little Green Pharma announced the first shipment of cannabis flower medicine from its recently acquired Danish facility had arrived in Australia. Additionally, the company shared news of 2 key appointments.

The cannabis flower medicine is named Billy Buttons THC 16 and has a THC content of 16%. The company is selling Billy Buttons to the Australian market in 15-gram packs.  

Little Green Pharma expects to receive another 2 shipments from its facility in Denmark before the end of October.

Little Green Pharma also announced it had appointed the former managing director of its Danish facility, Morten Snede, as its new Chief Financial Officer. It also brought the former managing director of Tasmanian Botanics, Tony Roberts, on board as its new general manager.

The Little Green Pharma share price gained 4% on the back of the day's news.

The following day, the company announced it was to venture into supplying psychedelic medicines.

Western Australia's Department of Health granted Little Green Pharma a licence to supply psilocybin. As a result, the company formed a subsidiary to conduct its psychedelic business.

Psilocybin can be used to treat mental illness.

Following the announcement, the Little Green Pharma share price gained 6.4%.

Unfortunately, its gains didn't hold. Since then, the company's share price has fallen 14.6% for no apparent reason.

Little Green Pharma share price snapshot

Despite its recent dip, Little Green Pharma's stock has been performing well on the ASX.

It is currently 25% higher than it was at the start of 2021. It has also gained 150% since this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Cannabis Shares

Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

Read more »